FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.6  |  FHIR Version n/a  User: [n/a]

773879000: Antineoplastic therapeutic role (role)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 31-Jan 2019. Module: SNOMED CT core module

Descriptions:

Id Description Lang Type Status Case? Module
3726859011 Antineoplastic therapeutic role en Synonym Active Entire term case insensitive SNOMED CT core module
3726860018 Antineoplastic therapeutic role (role) en Fully specified name Active Entire term case insensitive SNOMED CT core module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Antineoplastic therapeutic role Is a Therapeutic role true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing precisely umbralisib (as umbralisib tosylate) 200 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only umbralisib (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing umbralisib (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing lisocabtagene maraleucel (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only lisocabtagene maraleucel (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing lisocabtagene maraleucel in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only lisocabtagene maraleucel in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 20 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 15 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely olaparib 50 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ponatinib (as ponatinib hydrochloride) 30 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely aflibercept 40 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely anagrelide (as anagrelide hydrochloride) 1 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely eribulin (as eribulin mesilate) 440 microgram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely dacomitinib 15 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely dacomitinib 30 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely dacomitinib 45 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely nilotinib (as nilotinib hydrochloride) 150 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing idecabtagene vicleucel (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only idecabtagene vicleucel (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing idecabtagene vicleucel in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only idecabtagene vicleucel in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely vemurafenib 240 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Dostarlimab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing dostarlimab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing dostarlimab (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only dostarlimab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely imatinib (as imatinib mesilate) 50 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely methyl aminolevulinate (as methyl aminolevulinate hydrochloride) 168 milligram/1 gram conventional release cutaneous cream (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing loncastuximab tesirine (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only loncastuximab tesirine (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing loncastuximab tesirine in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only loncastuximab tesirine in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ibrutinib 140 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ibrutinib 420 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ibrutinib 560 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ibrutinib 280 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely idelalisib 100 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely lorlatinib 100 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely lorlatinib 25 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely dasatinib 100 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely dasatinib 80 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely dasatinib 140 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing peginterferon beta-1a in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only peginterferon beta-1a in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon beta-1a (as peginterferon beta-1a) 250 microgram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely methotrexate (as methotrexate sodium) 2.5 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely methotrexate (as methotrexate sodium) 5 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely methotrexate (as methotrexate sodium) 10 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely methotrexate (as methotrexate sodium) 15 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely methotrexate (as methotrexate sodium) 7.5 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing sotorasib (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only sotorasib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely sotorasib 120 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Sotorasib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing sotorasib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing infigratinib (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only infigratinib (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing infigratinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only infigratinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely infigratinib 25 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely infigratinib 100 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing amivantamab (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Amivantamab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only amivantamab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing amivantamab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely triptorelin (as triptorelin pamoate) 22.5 milligram/1 vial powder for conventional release suspension for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely azacitidine 100 milligram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely lurbinectedin 4 milligram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely mitomycin 5 milligram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely abemaciclib 150 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely abemaciclib 100 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely abemaciclib 50 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely encorafenib 75 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely encorafenib 50 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely trastuzumab 120 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely nelarabine 5 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely nivolumab 10 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely osimertinib (as osimertinib mesilate) 80 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely osimertinib (as osimertinib mesilate) 40 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely methotrexate (as methotrexate sodium) 20 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely zanubrutinib 80 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely tivozanib (as tivozanib hydrochloride) 890 microgram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely tivozanib (as tivozanib hydrochloride) 1.34 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely melphalan flufenamide (as melphalan flufenamide hydrochloride) 20 milligram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely mercaptopurine 20 milligram/1 milliliter conventional release oral suspension (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely bendamustine hydrochloride 90 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carboplatin 10 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely cisplatin 1 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely oxaliplatin 5 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely etoposide 20 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely talazoparib (as talazoparib tosylate) 1 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely docetaxel 20 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely docetaxel 40 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely dacarbazine (as dacarbazine citrate) 100 milligram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely niraparib (as niraparib tosylate) 100 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely talazoparib (as talazoparib tosylate) 250 microgram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon alfa-2a (as peginterferon alfa-2a) 180 microgram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ifosfamide 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely blinatumomab 38.5 microgram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely bendamustine hydrochloride 25 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier

Start Previous Page 15 of 26 Next End

This concept is not in any reference sets

Back to Start